Kombiglyze XR FDA Approval History
FDA Approved: Yes (First approved November 5, 2010)
Brand name: Kombiglyze XR
Generic name: saxagliptin and metformin
Dosage form: Extended-Release Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2
Kombiglyze XR (saxagliptin and metformin) is a once-daily fixed dose combination of the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza (saxagliptin) and extended release metformin for the treatment of type 2 diabetes.
Development timeline for Kombiglyze XR
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
